Brokers Offer Predictions for CVKD Q1 Earnings

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Cadrenal Therapeutics in a research report issued on Tuesday, April 7th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($1.29) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($7.59) per share. HC Wainwright also issued estimates for Cadrenal Therapeutics’ Q2 2026 earnings at ($1.33) EPS, Q3 2026 earnings at ($0.79) EPS, Q4 2026 earnings at ($0.90) EPS, FY2026 earnings at ($4.01) EPS, FY2027 earnings at ($3.91) EPS and FY2028 earnings at ($2.33) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $13.00.

Cadrenal Therapeutics Trading Up 2.5%

Cadrenal Therapeutics stock opened at $4.97 on Thursday. Cadrenal Therapeutics has a twelve month low of $4.21 and a twelve month high of $17.50. The stock’s fifty day simple moving average is $6.39 and its 200-day simple moving average is $9.14. The firm has a market capitalization of $12.46 million, a P/E ratio of -0.74 and a beta of 1.53.

Cadrenal Therapeutics (NASDAQ:CVKD) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.24).

Hedge Funds Weigh In On Cadrenal Therapeutics

Large investors have recently bought and sold shares of the business. DRW Securities LLC purchased a new position in Cadrenal Therapeutics in the fourth quarter valued at $171,000. Citadel Advisors LLC purchased a new position in Cadrenal Therapeutics in the third quarter valued at $274,000. JPMorgan Chase & Co. purchased a new position in Cadrenal Therapeutics in the third quarter valued at $103,000. Finally, Geode Capital Management LLC increased its holdings in Cadrenal Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after buying an additional 1,818 shares during the last quarter. Hedge funds and other institutional investors own 7.92% of the company’s stock.

Key Stories Impacting Cadrenal Therapeutics

Here are the key news stories impacting Cadrenal Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $13 price target and published multi‑year EPS forecasts that show losses narrowing (FY2026: ($4.01), FY2027: ($3.91), FY2028: ($2.33)). That less‑negative trajectory versus the consensus may support upside expectations and investor buying interest.
• Positive Sentiment: New data coverage highlights 12‑LOX inhibition as a mechanism to target inflammation tied to obesity and type 2 diabetes — a positive clinical signal for Cadrenal’s pipeline given the large addressable market and potential validation of mechanism. Article Title
• Neutral Sentiment: Zacks Research updated quarterly EPS models (Q1–Q4 2026) projecting roughly ($1.30)–($1.38) per quarter and reiterates the consensus full‑year loss view (≈($7.59)). These are model updates rather than new catalysts and mainly provide short‑term visibility on expected cash burn and dilution needs.
• Negative Sentiment: Cadrenal reported a Q1 quarter (announced March 31) EPS miss — ($1.41) vs. consensus ($1.17) — underscoring current operating losses and the need for financing or milestone progress to materially change the outlook.
• Negative Sentiment: Press coverage framed HC Wainwright’s projections as bearish for the stock price in some outlets, which can amplify selling pressure among short‑term traders despite the firm’s “Buy” call. Article Title

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.